Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.62 |
| ▸ | HTR7 | P34969 | 6/20 | 0.57 |
| ▸ | HTR1A | P08908 | 5/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.57 |
| ▸ | HTR3B | O95264 | 4/20 | 0.57 |
| ▸ | HTR3A | P46098 | 4/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28861545 | 0.98 | ADRB1 (0.60) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL16019525 | 0.87 | NOTUM (0.56) | ADRB1HTR3ADRD2DRD3ALDH1A1 | |
| SCHEMBL6260125 | 0.87 | ADRB1 (0.58) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL3849924 | 0.86 | ADRB1 (0.58) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL27773656 | 0.85 | THRB (0.58) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL8280092 | 0.84 | ADRB1 (0.60) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL3534359 | 0.84 | NOTUM (0.54) | ADRB1DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL14349225 | 0.84 | NOTUM (0.54) | ADRB1DRD2DRD3ALDH1A1NOTUM | |
| SCHEMBL8436656 | 0.83 | ADRB1 (0.55) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL8440963 | 0.83 | ADRB1 (0.55) | ADRB1HTR7HTR1AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3793990-B1 | ANTIBACTERIAL COMPOUNDS | INFEX THERAPEUTICS LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-02-23 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| CN-1812790-A | 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor | WYETH CORP (US) | 2006-08-02 | — | — | CN | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ADRB1 1589/4885HTR7 1017/4885HTR1A 1451/4885 |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | ADRB1 292/4885HTR7 3710/4885HTR1A 3682/4885 |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | GAA, MGAM, NQO1 | ADRB1 2580/4885HTR7 4848/4885HTR1A 4774/4885 |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | ADRB1 1997/4885HTR7 4487/4885HTR1A 3766/4885 |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | ADRB1 2441/4885HTR7 2576/4885HTR1A 3731/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | ADRB1 4110/4885HTR7 4806/4885HTR1A 4682/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | ADRB1 4481/4885HTR7 4826/4885HTR1A 4709/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ADRB1 2563/4885HTR7 1626/4885HTR1A 2200/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | ADRB1 2114/4885HTR7 4142/4885HTR1A 3787/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | ADRB1 1583/4885HTR7 4641/4885HTR1A 4686/4885 |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | ADRB1 4529/4885HTR7 1495/4885HTR1A 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.